Patent Application
20200017862
This application contains a sequence listing filed in electronic form as an ASCII.txt file entitled 222118-2020_ST25.txt, created on Dec. 11, 2017 and having a size of 14 KB. The content of the sequence listing is incorporated herein in its entirety.
DNA single-strand breaks (SSBs) are generated approximately 10,000 time per day per mammalian cell and considered as the most common type of DNA damage. SSBs result from various cellular processes, including, but not limited to, unbalanced reactive oxygen species, intermediate products of DNA repair pathways such as base excision repair (BER), and aborted activity of cellular enzymes such as Topoisomerase 1 (Top1) (Caldecott, 2008; Yan et al., 2014). If not repaired properly or promptly, SSBs lead to genome instability and have been associated with the pathologies of cancer and neurodegenerative disorders (Caldecott, 2008; Yan et al., 2014). However, it remains unknown how cells sense and recognize unrepaired SSBs in their genome to trigger a DNA damage response (DDR) pathway.
Several critical barriers hinder understanding of SSB signaling at molecular level. The first critical barrier for SSB signaling is the lack of a defined experimental system to dissect all aspects of SSB signaling. Cellular signaling to double-strand breaks (DSBs) has been studied via generating a single site-specific DSB in a genome by HO or I-Scel endonuclease in yeast and mammalian cells (Costelloe et al., 2012; Hicks et al., 2011; Richardson and Jasin, 2000; Rudin and Haber, 1988). Current understanding of SSB signaling comes primarily from an experimental system using indirect generation of SSBs after treatment of exogenous reagents such as hydrogen peroxide or methyl methanesulfonate (MMS) (Khoronenkova and Dianov, 2015; Willis et al., 2013). Spatial and temporal cellular response to multiple SSBs induced by UVDE (UV damage endonuclease) was characterized in human cells (Okano et al., 2003). The second critical barrier for SSB signaling is the inability in existing systems to distinguish SSBs from DSBs. Many DNA damaging reagents generate both SSBs and DSBs simultaneously or sequentially. Thus, with current technology, it is extremely difficult to directly explore SSB signaling exclusively in response to SSBs, as opposed to a combination of SSBs and DSBs. Thus, it remains unknown whether a defined SSB structure triggers a specific SSB signaling for a DDR pathway.
In various embodiments, the present disclosure provides defined site-specific single-strand break (SSB) plasmid structure that can trigger an SSB DNA damage response (DDR) pathway in a eukaryotic cell-free system, as well as systems and kits including the SSB plasmid structure and methods of making the SSB plasmid structure and methods of using the structure and system to identify modulators of DDR activity for SSB repair. The present disclosure also provides methods for modulating the defined SSB signaling as well as methods of screening for one or more modulators of SSB mediated DDR activity, and methods of inhibiting SSB repair.
Embodiments of a site-specific, single-strand break (SSB) plasmid structure of the present disclosure include an engineered plasmid, where the plasmid is a double-stranded, circular plasmid having an inner (−) and outer (+) strand, the engineered plasmid genetically modified to have a single recognition site for a specific restriction enzyme, where the single restriction site is located on the + strand of the plasmid, such that contacting the plasmid with the specific restriction enzyme results in a single nick in the + strand only.
Methods of making a site-specific, single-strand break (SSB) plasmid structure of the present disclosure are provided in the present disclosure. Embodiments of such methods can include providing a genetically engineered plasmid having a single recognition site for a specific restriction enzyme located on the outer (+) strand of the plasmid DNA and contacting the plasmid with the specific restriction enzyme to generate a single-strand break in the + strand of the plasmid to produce a SSB plasmid structure.
Embodiments of a cell-free single-strand break (SSB) repair and signaling system of the present disclosure can include an engineered site-specific, SSB plasmid structure comprising a single nick in a double-stranded, circular plasmid having an inner (−) and outer (+) strand, wherein the nick is located at a single restriction site in the + strand of the plasmid, and a high-speed supernatant (HSS) from Xenopus egg extracts.
The present disclosure also provides methods for identifying modulators of DNA damage response (DDR) activity for single-strand break (SSB) repair. Embodiments of such methods include providing a composition including a plurality of engineered site-specific, SSB plasmid structures, each having a single nick in a double-stranded, circular plasmid having an inner (−) and outer (+) strand, where the nick is located at a single restriction site in the + strand of the plasmid; and providing a high-speed supernatant (HSS) from Xenopus egg extract, where incubating the engineered site-specific, SSB plasmid structure in the HSS results in one or more SSB DNA damage response (DDR) activities; combining the engineered site-specific, SSB plasmid structure with the HSS and a test compound to make a test mixture; and detecting SSB DDR activity.
Systems for high-throughput identification of small-molecule modulators of DNA damage response (DDR) activity for single-strand break (SSB) repair are provided in the present disclosure. Embodiments of these systems can include an array with a plurality of spots, each spot including: a composition comprising a plurality of engineered site-specific, SSB plasmid structures, each having a single nick in a double-stranded, circular plasmid having an inner (−) and outer (+) strand, where the nick is located at a single restriction site in the + strand of the plasmid; and a high-speed supernatant (HSS) from Xenopus egg extracts. In embodiments, at least a portion of the spots on the array are test spots and wherein each test spot independently includes a different test compound from a library of small-molecules and a detection substrate capable of producing a detectable signal upon occurrence of an SSB DDR activity, where a reduced or increased SSB DDR activity compared to the SSB DDR activity in the absence of the test compound indicates that the test compound modulates SSB DDR activity.
In embodiments, the present disclosure provides methods of inhibiting single-strand break (SSB) repair, such methods including contacting a composition comprising DNA molecules, wherein at least a portion of the DNA molecules have single-strand breaks, with an effective amount of a small molecule inhibitor 3-Hydroxy-9β,13α-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid (Celastrol).
Methods of the present disclosure also include methods for actively inhibiting single-strand break (SSB) repair in at least one cell. In embodiments, such methods can include the step of contacting at least one cell with an effective amount of 3-Hydroxy-9β,13α-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid.
In embodiments, the present disclosure also includes a kit comprising a site-specific, single-strand break (SSB) plasmid structure of the present disclosure, and one or more of: (a) a high-speed supernatant (HSS) from Xenopus egg extract; (b) a detection substrate for detecting SSB DDR activity; or (d) instructions for identifying modulators of DNA damage response (DDR) activity for single-strand break (SSB) repair.
Other compositions, apparatus, methods, features, and advantages will be or become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional compositions, apparatus, methods, features and advantages be included within this description, be within the scope of the present disclosure, and be protected by the accompanying claims.
Further aspects of the present disclosure will be more readily appreciated upon review of the detailed description of its various embodiments, described below, when taken in conjunction with the accompanying drawings.
Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
All publications and patents cited in this specification that are incorporated by reference, as noted in the application, are incorporated by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, organic chemistry, biochemistry, genetic engineering, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
It must be noted that, as used in the specification and the appended embodiments, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a support” includes a plurality of supports. In this specification and in the embodiments that follow, reference will be made to a number of terms that shall be defined to have the following meanings unless a contrary intention is apparent.
As used herein, the following terms have the meanings ascribed to them unless specified otherwise. In this disclosure, “consisting essentially of” or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure refers to compositions like those disclosed herein, but which may contain additional structural groups, composition components or method steps (or analogs or derivatives thereof as discussed above). Such additional structural groups, composition components or method steps, etc., however, do not materially affect the basic and novel characteristic(s) of the compositions or methods, compared to those of the corresponding compositions or methods disclosed herein. “Consisting essentially of” or “consists essentially” or the like, when applied to methods and compositions encompassed by the present disclosure have the meaning ascribed in U.S. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.
Prior to describing the various embodiments, the following definitions are provided and should be used unless otherwise indicated.
In describing the disclosed subject matter, the following terminology will be used in accordance with the definitions set forth below.
As used herein, “about,” “approximately,” and the like, when used in connection with a numerical variable, generally refers to the value of the variable and to all values of the variable that are within the experimental error (e.g., within the 95% confidence interval for the mean) or within +1-10% of the indicated value, whichever is greater.
The terms “nucleic acid” and “polynucleotide” are terms that generally refer to a string of at least two base-sugar-phosphate combinations. As used herein, the terms include deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and generally refer to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. RNA may be in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, RNAi (RNA interference construct), siRNA (short interfering RNA), or ribozymes. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. The terms “nucleic acid sequence” and “oligonucleotide” also encompasses a nucleic acid and polynucleotide as defined above.
In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide.
It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia. For instance, the term polynucleotide includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.
The term also includes PNAs (peptide nucleic acids), phosphorothioates, and other variants of the phosphate backbone of native nucleic acids. Natural nucleic acids have a phosphate backbone, artificial nucleic acids may contain other types of backbones, but contain the same bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are “nucleic acids” or “polynucleotides” as that term is intended herein.
A “gene” typically refers to a hereditary unit corresponding to a sequence of DNA that occupies a specific location on a chromosome and that contains the genetic instruction for a characteristic(s) or trait(s) in an organism and its regulatory sequences.
As used herein, “isolated” means removed or separated from the native environment. Therefore, isolated DNA can contain both coding (exon) and noncoding regions (introns) of a nucleotide sequence corresponding to a particular gene. An isolated peptide or protein indicates the protein is separated from its natural environment. Isolated nucleotide sequences and/or proteins are not necessarily purified. For instance, an isolated nucleotide or peptide may be included in a crude cellular extract or they may be subjected to additional purification and separation steps.
With respect to nucleotides, “isolated nucleic acid” refers to a nucleic acid with a structure (a) not identical to that of any naturally occurring nucleic acid or (b) not identical to that of any fragment of a naturally occurring genomic nucleic acid spanning more than three separate genes, and includes DNA, RNA, or derivatives or variants thereof. The term covers, for example but not limited to, (a) a DNA which has the sequence of part of a naturally occurring genomic molecule but is not flanked by at least one of the coding sequences that flank that part of the molecule in the genome of the species in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic nucleic acid of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any vector or naturally occurring genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), ligase chain reaction (LCR) or chemical synthesis, or a restriction fragment; (d) a recombinant nucleotide sequence that is part of a hybrid gene, e.g., a gene encoding a fusion protein, and (e) a recombinant nucleotide sequence that is part of a hybrid sequence that is not naturally occurring. Isolated nucleic acid molecules of the present disclosure can include, for example, natural allelic variants as well as nucleic acid molecules modified by nucleotide deletions, insertions, inversions, or substitutions.
It is advantageous for some purposes that a nucleotide sequence is in purified form. The term “purified” in reference to nucleic acid represents that the sequence has increased purity relative to the natural environment.
The term “polypeptides” and “protein” include proteins and fragments thereof. Polypeptides are disclosed herein as amino acid residue sequences. Those sequences are written left to right in the direction from the amino to the carboxy terminus. In accordance with standard nomenclature, amino acid residue sequences are denominated by either a three letter or a single letter code as indicated as follows: Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cysteine (Cys, C), Glutamine (Gln, Q), Glutamic Acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (Ile, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, VV), Tyrosine (Tyr, Y), and Valine (Val, V).
“Variant” refers to a polypeptide that differs from a reference polypeptide, but retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and/or deletions). A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.
Modifications and changes can be made in the structure of the polypeptides of in disclosure and still obtain a molecule having similar characteristics as the polypeptide (e.g., a conservative amino acid substitution). For example, certain amino acids can be substituted for other amino acids in a sequence without appreciable loss of activity. Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide's biological functional activity, certain amino acid sequence substitutions can be made in a polypeptide sequence and nevertheless obtain a polypeptide with like properties.
In making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still result in a polypeptide with similar biological activity. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).
It is believed that the relative hydropathic character of the amino acid determines the secondary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and the like. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.
Substitution of like amino acids can also be made on the basis of hydrophilicity, particularly, where the biological functional equivalent polypeptide or peptide thereby created is intended for use in immunological embodiments. The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (−0.5±1); threonine (−0.4); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.
As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gln, His), (Asp: Glu, Cys, Ser), (Gln: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gln), (Ile: Leu, Val), (Leu: Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe), and (Val: Ile, Leu). Embodiments of this disclosure thus contemplate functional or biological equivalents of a polypeptide as set forth above. In particular, embodiments of the polypeptides can include variants having about 50%, 60%, 70%, 80%, 90%, and 95% sequence identity to the polypeptide of interest.
As used herein “functional variant” refers to a variant of a protein or polypeptide (e.g., a variant of a CCD enzyme) that can perform the same functions or activities as the original protein or polypeptide, although not necessarily at the same level (e.g., the variant may have enhanced, reduced or changed functionality, so long as it retains the basic function).
“Identity,” as known in the art, is a relationship between two or more polypeptide sequences, as determined by comparing the sequences. In the art, “identity” also refers to the degree of sequence relatedness between polypeptide as determined by the match between strings of such sequences. “Identity” and “similarity” can be readily calculated by known methods, including, but not limited to, those described in (Computational Molecular Biology, Lesk, A. M., Ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., Ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., Eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., Eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J Applied Math., 48: 1073 (1988).
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. The percent identity between two sequences can be determined by using analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, Madison Wis.) that incorporates the Needelman and Wunsch, (J. Mol. Biol., 48: 443-453, 1970) algorithm (e.g., NBLAST, and XBLAST). The default parameters are used to determine the identity for the polypeptides of the present disclosure.
By way of example, a polypeptide sequence may be identical to the reference sequence, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the identity is less than 100%. Such alterations are selected from: at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in the reference polypeptide by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in the reference polypeptide.
As used herein, the term “engineered” indicates that the engineered object is created and/or altered by human intervention. An engineered object may include naturally derived substances, but the object itself is altered in some way by human intervention and design. For instance, an “engineered” or “genetically engineered” plasmid refers to a plasmid that has been altered in some way (e.g., by genetic modification) by human intervention.
The term “expression” as used herein describes the process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation. Expression generally refers to the “expression” of a nucleic acid to produce a polypeptide, but it is also generally acceptable to refer to “expression” of a polypeptide, indicating that the polypeptide is being produced via expression of the corresponding nucleic acid.
As used herein, the term “over-expression” and “up-regulation” refers to the expression of a nucleic acid encoding a polypeptide (e.g., a gene) in a genetically modified cell or cell-free system at higher levels (therefore producing an increased amount of the polypeptide encoded by the gene) than the “wild type” cell or system (e.g., a substantially equivalent cell or system that is not transfected with the gene) under substantially similar conditions. Thus, to over-express or increase expression of a target nucleic acid refers to increasing or inducing the production of the target polypeptide encoded by the nucleic acid, which may be done by a variety of approaches, such as increasing the number of genes encoding for the polypeptide, increasing the transcription of the gene (such as by placing the gene under the control of a constitutive promoter), or increasing the translation of the gene, or a combination of these and/or other approaches. Conversely, “under-expression” and “down-regulation” refers to expression of a polynucleotide (e.g., a gene) at lower levels (producing a decreased amount of the polypeptide encoded by the polynucleotide) than in a “wild type” cell or cell free system. As with over-expression, under-expression can occur at different points in the expression pathway, such as by decreasing the number of gene copies encoding for the polypeptide, inhibiting (e.g., decreasing or preventing) transcription and/or translation of the gene (e.g., by the use of antisense nucleotides, suppressors, knockouts, antagonists, etc.), or a combination of such approaches.
As used herein, the term “increase”, with respect to an activity, process, status, etc., refers to a measurably greater occurrence of such activity/process/status under certain circumstances and/or environments, as compared to a comparative circumstance or environment. Similarly, the term “decrease,” with respect to an activity, process, status, etc., refers to a measurably lesser occurrence of such activity/process/status in a certain circumstance or environment, as compared to a comparative circumstance or environment. For example, an increase in phosphorylation of a particular target peptide in a particular circumstance (e.g., in the presence of a particular test compound) exists when there is a greater occurrence of phosphorylation of that target peptide under the particular circumstances as compared to a control circumstance (e.g., the absence of the particular test compound).
The term “plasmid” as used herein refers to a non-chromosomal, double-stranded DNA sequence including an intact “replicon” such that the plasmid is replicated in a host cell. Plasmids can be linear or circular. Circular plasmids can be described as having an inner and outer strand. The outer strand is referred to herein as the “+ strand,” and the inner strand as the “− strand.”
As used herein, the term “expression system” includes a biologic system (e.g., a cell based system) used to express a polynucleotide to produce a protein. Such systems generally employ a plasmid or vector including the polynucleotide of interest, where the plasmid of expression vector is constructed with various elements (e.g., promoters, selectable markers, etc.) to enable expression of the protein product from the polynucleotide. Expression systems use the host system/host cell transcription and translation mechanisms to express the product protein. Common expression systems include, but are not limited to, bacterial expression systems (e.g., E. coli), yeast expression systems, viral expression systems, animal expression systems, and plant expression systems.
As used herein, the term “promoter” or “promoter region” includes all sequences capable of driving transcription of a coding sequence. In particular, the term “promoter” as used herein refers to a DNA sequence generally described as the 5′ regulator region of a gene, located proximal to the start codon. The transcription of an adjacent coding sequence(s) is initiated at the promoter region. The term “promoter” also includes fragments of a promoter that are functional in initiating transcription of the gene.
The term “operably linked” indicates that the regulatory sequences necessary for expression of the coding sequences of a nucleic acid are placed in the nucleic acid molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence. This same terminology is sometimes applied to the arrangement of coding sequences and transcription control elements (e.g. promoters, enhancers, and termination elements), and/or selectable markers in an expression vector.
The terms “native,” “wild type”, or “unmodified” in reference to an organism (e.g., plant or cell), polypeptide, protein or enzyme, are used herein to provide a reference point for a variant/mutant of an organism, polypeptide, protein, or enzyme prior to its mutation and/or modification (whether the mutation and/or modification occurred naturally or by human design). Typically, the unmodified, native, or wild type organism, polypeptide, protein, or enzyme has an amino acid sequence that corresponds substantially or completely to the amino acid sequence of the polypeptide, protein, or enzyme as it typically/predominantly occurs in nature.
As used herein, the term “library” refers to a collection of items (e.g., group of sDNA sequences, peptides, group of small molecule chemical compounds, group of cells, group of organisms, etc.), where most of the individual items in the library differ from every other item (or substantially every other item; some small percentage of repeats may be unavoidable) in some aspect.
The term “detectable” refers to the ability to perceive or distinguish a signal over a background signal. “Detecting” refers to the act of determining the presence of and recognizing a target or the occurrence of an event by perceiving a signal that indicates the presence of a target or occurrence of an event, where the signal is capable of being perceived over a background signal. As used herein a “detection substrate” is a substrate that, when acted upon, produces a detectable signal.
The term “phosphorylatable” refers to a target peptide that is capable of being phosphorylated (e.g., having a phosphoryl group coupled to it) by an enzyme, typically a kinase). Phosphorylation/dephosphorylation typically leads to activation or deactivation of many proteins, thereby regulating function. Phosphorylation can occur on several amino acid side chains, such as, serine, threonine, and tyrosine, when those amino acid residues are in a conformation such that they are accessible to a kinase. In embodiments, a “phosphorylatable peptide” refers to a peptide that is phosphorylatable (e.g., by inclusion of a phosphorylatable amino acid residue). Conversely, a “non-phosphorylatable peptide” refers to a peptide that cannot be phosphorylated (e.g., by lacking an exposed phosphorylatable amino acid). For instance, a peptide described below having SEQ ID NO: 4 is phosphorylatable at the serine residue at aa 10, whereas the peptide described below having SEQ ID NO: 5 is not phosphorylatable, because in place of the serine, it has an alanine residue at aa 10.
In embodiments, the phosphorylation of a target peptide can serve as a “detection substrate” for producing a “detectable signal” in the methods and systems of the present disclosure.
As used herein, the term “single-strand break DNA damage response activity” (SSB DDR activity) refers to the occurrence of one or more activates related to a series of sub-cellular events in a DNA response and repair process initiated by the occurrence and recognition of a single-strand break in a double stranded DNA molecule, which events include, but are not limited to, recognition of a single-strand break, signaling related to the single-strand break, recruitment and activation of various compounds involved in the DDR pathway, and culminating with the repair of the single-strand break. Examples of events that can occur during this process and thus represent one or more “SSB DDR activities” include, but are not limited to recruitment of APE2 to the site of a SSB, interaction of the PIP (PCNA interaction protein) box of APE2 with the PCNA-IDCL (interdomain connector loop), interaction of the APE2 zinc-finger motif (Zf-GRF) with the PCNA CTM and/or the portion of ssDNA at the site of the SSB, APE2 exonuclease activity, binding of RPA to the ssDNA, recruitment of ATR and ATRIP to the region of ssDNA, phosphorylation of Chk1 by ATR, interaction of the 911 complex and/or TopBP1 with the region of ssDNA to repair the SSB and restore the dsDNA. In embodiments, the ATR phosphorylation of Chk1 via APE2 recruitment and activation is used as a SSB DDR activity that indicates activation of the SSB DDR pathway.
By “administration” is meant introducing a compound of the present disclosure into a subject; it may also refer to the act of providing a composition of the present disclosure to a subject (e.g., by prescribing).
The term “effective amount” refers to that amount of the compound being administered which will produce a reaction that is distinct from a reaction that would occur in the absence of the compound. The term “therapeutically effective amount” as used herein refers to that amount of the compound being administered which will relieve or prevent to some extent one or more of the symptoms of the condition to be treated. In reference to conditions/diseases that can be directly treated with a composition of the disclosure, a therapeutically effective amount refers to that amount which has the effect of preventing the condition/disease from occurring in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the condition/disease (prophylactic treatment), alleviation of symptoms of the condition/disease, diminishment of extent of the condition/disease, stabilization (e.g., not worsening) of the condition/disease, preventing the spread of condition/disease, delaying or slowing of the condition/disease progression, amelioration or palliation of the condition/disease state, and combinations thereof.
Embodiments of the present disclosure encompass structures, systems, and methods for modeling and analysis of single-strand break (SSB) signaling and repair in a cell-free system, methods of making the SSB structures and systems, methods and systems for identifying modulators of DNA damage response (DDR) activity for SSB repair, and methods of inhibiting SSB repair.
Some mechanisms and principles of cellular response to DNA damage (single or double strand breaks, etc.) have been studied. It is generally accepted that cellular response to DNA damage and replication stress is mainly coordinated by ATR-Chk1 and ATM-Chk2 DNA damage response (DDR) pathways (Bartek et al., 2004; Branzei and Foiani, 2010; Harper and Elledge, 2007; Harrison and Haber, 2006; Su, 2006). Mechanisms to activate the ATR-Chk1 DDR pathway include, but are not necessarily limited to stalled DNA replication forks, UV-damage, DSBs, or oxidative DNA damage (Ciccia and Elledge, 2010; Cimprich and Cortez, 2008). Full ATR activation requires several mediator proteins, such as ATRIP, TopBP1, MDC1, and the 9-1-1 (Rad9-Rad1-Hus1) complex (see, e.g.,
It is also generally accepted that RPA-coated long stretch of ssDNA serves as platform to recruit ATR and TopBP1 to sites of DNA damage, although the 9-1-1 complex prefers the 5′-recessed ssDNA/dsDNA junctions (Acevedo et al., 2016; Ellison and Stillman, 2003; Marechal and Zou, 2015; Zou and Elledge, 2003). Activated ATR kinase phosphorylates a variety of substrates including Chk1 to regulate cell cycle progress, activate transcription, and promote DNA repair (Matsuoka et al., 2007). Upon phosphorylation at the Ser345 or Ser317 residue of Chk1, Chk1 kinase will be fully activated, and Chk1 phosphorylation is often utilized as an indicator of ATR activation (Chen and Sanchez, 2004; Guo et al., 2000; Zhao and Piwnica-Worms, 2001). A two-step model for DNA end resection at DSB sites has been proposed through MRN (Mre11-Rad50-Nbs1) complex or CtIP/Sae2, and Exo1 or DNA2/Sgs1 (19). Furthermore, ATM can be activated through a disulfide bond formation and conformation change in oxidative stress in a DNA-independent manner (20,21).
Although both SSBs and DSBs activate the DDR pathways, the repair signaling and mechanisms for SSBs are probably less understood. SSBs lead to genome instability and have been associated with various pathologies, and although ATM can be activated by presumptive unrepaired SSBs in XRCC1-deficient cells, it remains unknown how exactly unrepaired SSBs activate ATM DDR pathway (21). As mentioned above, the lack of a defined SSB experimental system and the inability to distinguish SSBs from DSBs has hindered further understanding of SSB recognition and repair pathways.
Whereas APE1 is the major AP endonuclease (26), APE2 (APEX2, APN2) has strong 3′-5′ exonuclease and 3′-phosphodiesterase activities but weak AP endonuclease activity (27). APE2 is involved in normal B cell development and recovery from chemotherapy drug-induced DNA damage (28). The interdomain connector loop (IDCL) of PCNA associates with the PIP (PCNA interaction protein) box of its interacting proteins (29). The PIP box of APE2 is important for PCNA association (24,30,31). Importantly, APE2 is a key player in PCNA-dependent repair of hydrogen peroxide-induced oxidative DNA damage (30,31). It has been demonstrated that ATR-Chk1 DDR pathway is activated by hydrogen peroxide-induced oxidative stress in Xenopus, and that APE2 is important for the oxidative stress-induced ATR-Chk1 checkpoint signaling (24). Notably, the examples below demonstrate that a zinc-finger motif (referred to herein as Zf-GRF) in APE2's C-terminus associates with ssDNA, but not dsDNA, and that APE2 Zf-GRF facilitates 3′-5′ end resection of oxidative DNA damage to promote ATR-Chk1 DDR pathway (32).
As a cell-free experimental system from eggs of the African clawed frogs, Xenopus egg extracts have been widely used in studies of chromosome metabolisms, and findings from Xenopus system can be validated in mammalian cell lines (Costanzo and Gautier, 2004; Deming and Kornbluth, 2006; Kumagai and Dunphy, 2000; Lebofsky et al., 2009; Lupardus et al., 2002; Michael et al., 2000; Philpott and Yew, 2008; Raschle et al., 2008; Tutter and Walter, 2006; Willis et al., 2012). Three different types of Xenopus egg extracts have been widely used: low-speed supernatant (LSS), high-speed supernatant (HSS), and nucleoplasmic extracts (NPE), discussed in greater detail below (Cupello et al., 2016; Walter et al., 1998). It has been demonstrated in recent studies that APE2 is required for the ATR-Chk1 checkpoint activation in response to oxidative stress-derived SSBs in Xenopus LSS system (Willis et al., 2013; Yan et al., 2014).
Based on the above studies, it was believed that a zinc-finger motif (designated as Zf-GRF) in APE2's C-terminus may associate with ssDNA and 3′-recessed ssDNA/dsDNA junction, but not dsDNA, and that APE2 Zf-GRF facilitates its 3′-5′ end resection of oxidative DNA damage to promote ATR-Chk1 DDR pathway in the LSS system (Wallace et al., 2017). However, this could not be confirmed in current systems, nor did a system exist for the exclusive study of SSB signaling and repair mechanisms, or identification of specific modulators of SSB DDR activities. The defined SSB structures and systems provided in embodiments of the present disclosure were developed for further investigation of the role of APE2 and other proteins in SSB-specific signaling and repair and for use in systems for the identification of modulators of SSB DDR pathway and activities. As discussed in greater detail in the Examples below, development and use of the defined SSB plasmid structure and systems of the present disclosure demonstrated that an ATR-dependent but replication-independent DDR pathway is activated by the defined SSB structure in the Xenopus HSS system. The Examples demonstrate that SSB signaling implements APE2 and canonical checkpoint proteins including ATR, ATRIP, TopBP1, Rad9, and Claspin. Surprisingly, it was found that APE2's Zf-GRF associates with PCNA through its C-terminus. The present disclosure also demonstrates that the distinct APE2-PCNA interaction plays a role for the 3′-5′ SSB end resection and SSB signaling in a eukaryotic system. In addition, the examples provide evidence that the SSB-induced ATR activation is important for SSB repair and that hydrogen peroxide triggers ATR-dependent DDR pathway in human cultured cells. Various embodiments of these structures, systems, and methods of the present disclosure are described below.
Single-Strand Break Plasmid Structures
Embodiments of the present disclosure provide site-specific, single-strand break (SSB) plasmid structures, methods of making them and methods of using the site-specific, SSB plasmid structures. Embodiments of the SSB plasmid structures are illustrated in
For instance, the unmodified plasmid pUC19 (SEQ ID NO: 1) has four recognition sites for the restriction enzyme Nt.BstNBI, two on the (+) strand and two on the (−) strand. In embodiments of the present disclosure, this plasmid is mutated to produce engineered site-specific SSB plasmid structure pS (SEQ ID NO: 2). The pUC19 plasmid is mutated by removing three of the Nt.BstNBI recognition sites and retain only one recognition site on the + strands (at nt 427-431 of SEQ ID NO: 2, which is within a portion of SEQ ID NO: 2 from nt 420-450, also named SEQ ID NO: 3, herein), as illustrated in
For purposes of comparison of the SSB to a DSB, in embodiments, the SSB plasmid structures of the present disclosure, in addition to the single recognition site for a specific restriction enzyme in the + strand, the pS plasmid also includes a single recognition site for another restriction enzyme such that contacting the plasmid with the other restriction enzyme results in a double-stranded break (DSB) in the plasmid structure, thereby linearizing the plasmid. In embodiments, a SSB plasmid structure of the present disclosure provides a genetically engineered pUC19 plasmid (the genetically engineered pUC19 plasmid is also referred to herein as pS plasmid) with a single recognition site for NT.BstNBI and further comprises a single recognition site for a SbfI restriction enzyme, such that contacting the plasmid with the SbfI restriction enzyme results in a double strand break (DSB) in the plasmid, linearizing the plasmid (as shown in
Embodiments of the present disclosure also include methods of making the site-specific, single-strand break SSB plasmid structures of the present disclosure. Such embodiments can include genetically engineering a plasmid to have a single recognition site for a specific restriction enzyme located on the outer (+) strand of the plasmid DNA. Methods include providing the genetically engineered plasmid having the single recognition site for a specific restriction enzyme in the (+) strand. The methods then include contacting the plasmid with the specific restriction enzyme (e.g., incubating the plasmid structure with a volume of the restriction enzyme) to generate a single-strand break in the + strand of the plasmid to produce a SSB plasmid structure. As mentioned above, this technique is described in the examples below with respect to the pUC19 plasmid to make the genetically engineered pS plasmid with a single recognition site for the restriction enzyme Nt.BstNBI; however, in practice different plasmid structures and different restriction enzymes/recognition sties can be used. In embodiments, the methods of making the site-specific SSB plasmid structure include contacting the plasmid with a phosphatase to remove a phosphate from a nicked 5′ end of the plasmid DNA at the location of the single-strand break. In embodiments the phosphatase may be contacted with the plasmid simultaneously with the restriction enzyme, or after contacting the plasmid with the specific restriction enzyme. The removal by the phosphatase at the nick site leaves both nicked ends with hydroxyl groups, thereby preventing spontaneous re-ligation of the SSB.
The site-specific SSB plasmid structures of the present disclosure can be included in cell-free, single-strand break (SSB) repair and signaling systems of the present disclosure, and used to identify modulators of DNA damage response (DDR) pathway.
Cell-Free Single-Strand Break (SSB) Repair and Signaling Systems and Kits
The present disclosure also provides cell-free SSB repair and signaling systems including the engineered site-specific, SSB plasmid structures of the present disclosure and a high-speed supernatant (HSS) from Xenopus egg extracts. As described above, the SSB plasmid structures have a single nick in the + strand of a double-stranded, circular plasmid where the nick is located at a single restriction site in the + strand of the plasmid. The Xenopus egg extract HSS is a composition obtained through specific processing of Xenopus egg extracts, and offers the advantage of being able to observe, manipulate, and study the SSB plasmid structures and SSB DDR activities in a cell-free environment.
Xenopus egg extracts derived from eggs of African clawed frogs have been utilized in studies of DNA replication, DNA repair, and DNA damage response (DDR) pathways (Costanzo and Gautier, 2004; Karpinka et al., 2015; Kumagai and Dunphy, 2000; Lupardus et al., 2002; Michael et al., 2000; Philpott and Yew, 2008; Raschle et al., 2008; Willis et al., 2013). There are several different types of Xenopus egg extracts: low-speed supernatant (i.e., LSS), high-speed supernatant (i.e., HSS), and nucleoplasmic extracts (i.e., NPE), the production and uses of which are illustrated in
Thus, in embodiments of the cell-free SSB repair and signaling system of the present disclosure, the HSS is obtained by the following steps: centrifuging Xenopus eggs at a speed of about 18,000-22,000 g for about 20-30 min; retaining a low-speed supernatant (LSS) layer; centrifuging the LSS at about 240,000-280,000 g, for about 90-120 min; and retaining the supernatant layer to produce the HSS. In embodiments the LSS is obtained after centrifuging the eggs at a speed of about 20,000 g for about 20 min. In embodiments, the HSS is obtained after centrifuging the LSS at a speed of about 260,000 g for about 90 min.
LSS, HSS, and NPE can be used for different purposes and analysis. For instance, after being added to the LSS, sperm chromatin DNA or bacteriophage lambda DNA can form nuclear envelope and be replicated in a semi-conservative manner, reconstituting an in vitro cell-free DNA replication system that mimics the in vivo DNA replication program in mammalian cells (Blow and Laskey, 1986; Newport, 1987). When DNA damaging agents are used to stress chromatin DNA in LSS system, immunoblotting analysis of proteins of interest (e.g., Chk1 phosphorylation at Ser 344 and ATM phosphorylation at Ser 1981) can dissect molecular mechanisms of DDR pathways (
Some advantages of the LSS system and the HSS/NPE system are that target proteins can be removed via immunodepletion with specific antibodies and that recombinant wild type or mutant proteins can be added back to depleted egg extracts. Another feature of Xenopus systems is that small molecules (e.g., ATM specific inhibitor KU55933 and ATR specific inhibitor VE-822) can be added to LSS or HSS to certain concentrations allowing analysis of the roles and mechanisms of these small molecules with respect to DDR pathways (see
Thus, in embodiments of the cell-free SSB repair and signaling system of the present disclosure, incubating the engineered site-specific, SSB plasmid structure in the HSS results in one or more DNA damage response (DDR) activities selected from the group consisting of: initiation of DDR processes, recruitment of DDR signaling molecules, formation of DDR protein complexes, and repair of the engineered site-specific, SSB plasmid structure to form an intact circular plasmid. In embodiments, one or more test compounds can be included and/or added to the cell-free SSB repair and signaling systems of the present disclosure. Incubating the engineered site-specific, SSB plasmid structure in the HSS with the test compound allows evaluation of the effect of the test compound on one or more of the DDR activities using the analysis approaches described above, such as immunoblotting analysis of cellular signaling molecules, immunoblotting for recruitment of various DDR proteins, or detection of a DDR event via a detectable signal, such as phosphorylation of a phosphorylatable protein involved in a DDR pathway (or a phosphorylatable peptide derived from such protein, as described in greater detail below).
Embodiments of the present disclosure also include kits including the SSB plasmid structures of the present disclosure described above and one or more of an HSS from Xenopus egg extract, a detection substrate for detecting SSB DDR activity, or instructions for identifying modulators of DDR activity for SSB repair. In embodiments, uch kits can include SSB plasmid structures, HSS, detection substrates, and instructions for identifying modulators.
Methods for Identifying Modulators of DNA Damage Response (DDR) Activity for Single-Strand Break (SSB) Repair
The present disclosure provides methods for identifying modulators of DNA damage response (DDR) activity for single-strand break (SSB) repair using the SSB plasmid structures and cell-free SSB repair and signaling systems of the present disclosure. In embodiments the methods for identifying modulators of DDR activity for SSB repair include providing a composition including a plurality of engineered site-specific, SSB plasmid structures of the present disclosure described above; providing a HSS from Xenopus egg extracts as described above; combining the engineered site-specific, SSB plasmid structure with the HSS and a test compound to make a test mixture; and detecting SSB DDR activity. In embodiments, the method includes screening the test mixture for one or more SSB DDR activities and detecting an SSB DDR activity. Since incubating the engineered site-specific, SSB plasmid structure in the HSS alone results in one or more SSB DDR activities (as described above and described in greater detail in the Examples below), then any changes in the SSB DDR activities (e.g., reduced or increased SSB DDR activity) seen in the presence of the test compound, as compared to the SSB DDR activity in the absence of the test compound, indicate that the test compound modulates an SSB DDR activity.
As described above, in embodiments, SSB DDR activities can be indicated by screening for conditions, such as, but not limited to, the presence of nicked SSB plasmids vs. repaired circular plasmids, the presence or activation (e.g., phosphorylation) of certain cellular signaling molecules, and the recruitment and/or activation of various DDR proteins onto SSB DNA in the HSS system, and the like. See,
In embodiments, the methods for identifying modulators of DDR activity for SSB repair of the present disclosure further includes adding a detection substrate to the tests mixture and screening for a detectable signal produced by the detection substrate upon the occurrence of one or more SSB DRR activities. ATR is a kinase capable of phosphorylating its substrates. Activation of ATR is a SSB DDR activity; thus, phosphorylation of an ATR kinase substrate (or a phosphorylatable peptide derived from an ATR kinase substrate) can be used as an indicator of SSB DRR activity. In embodiments, a detection substrate can be a phosphorylatable protein substrate of an ATR kinase or a phosphorylatable peptide derived from a substrate of ATR kinase to the test mixture, and screening for phosphorylation of such protein or peptide. Phosphorylation of a substrate by ATR kinase is a DDR activity. Thus, detecting phosphorylation of the phosphorylatable substrate of ATR kinase or peptide derived therefrom indicates the occurrence of a DDR activity, so a substrate of ATR kinase can act as a detection substrate for indicating occurrence of a SSB DDR activity. In embodiments detecting SSB DDR activity includes detecting phosphorylation of a phosphorylatable peptide derived from a substrate of ATR kinase.
In embodiments, a positive control spot without a test compound has a positive indicator of SSB DDR activity, such as phosphorylated peptide derived from a substrate of ATR kinase. Thus, in embodiments, a positive control produces a detectable phosphorylation signal to indicate SSB DDR Activity. In this manner, if the phosphorylation signal is detected in a test spot and is about the same or increased over the signal in a positive control spot that does not have the test compound, it indicates that the test compound increases or upregulates the DDR activity. If the phosphorylation signal is not detected in a test spot or the signal is decreased over the signal in the positive control spot that does not include the test compound, it indicates that the test compound decreases or suppresses/downregulates the DDR activity. Thus, methods of the present disclosure can also include comparing the SSB DDR activity level (as determined e.g., by detecting phosphorylation of a phosphorylatable detection substrate) in the presence of the test compound to the SSB DDR activity level in the absence of a test compound (e.g., in a control reaction or spot). Modulators of SSB DDR activity may be useful for a variety of reasons, such as cancer treatment, and the like.
One substrate of ATR is Chk1, and phosphorylated Chk1 is also an indicator of activated APE2 (see
The methods of identifying modulators of DDR activity for SSB repair of the present disclosure can also include an array with a plurality of spots, where each spot receives the plurality of engineered site-specific, SSB plasmid structures, the high-speed supernatant (HSS) from Xenopus egg extract, and a detection substrate and where a portion of the spots (e.g., test spots) independently receive a test compound. In embodiments, the detection substrate is a phosphorylateable peptide derived from a substrate of ATR kinase, such as described above. Such embodiments can be used in high-throughput systems for screening libraries of compounds for the ability to affect SSB repair activity and DDR pathway.
Systems for High-Throughput Identification of Modulators of DDR Activity for SSB Repair
The present disclosure provides systems for high-throughput identification of small-molecule modulators of DDR for SSB repair that use the methods of identifying modulators of DDR activity described above and the SSB plasmid structures and cell-free SSB repair and signaling systems described above.
In embodiments, systems for high-throughput identification of small-molecule modulators of DDR for SSB repair of the present disclosure include an array with a plurality of spots, such as illustrated in
In embodiments, such as illustrated in
In embodiments, the array also includes at least one positive control spot and at least one negative control spot, such as illustrated in
In embodiments, the detection substrate is a phosphorylatable Chk1-derived peptide and the phosphorylation of the phosphorylatable Chk1-derived peptide indicates occurrence of an SSB DDR activity in the test spot and absence or reduced phosphorylation of the phosphorylatable Chk1-derived peptide in the test spot indicates that the test compound suppresses or inhibits an SSB DDR activity. In embodiments, the positive indicator of SSB DDR activity in the positive control spot is the same phosphorylatable Chk1-derived peptide as the detection substrate and the negative indicator of SSB DDR activity in the negative control spot is a non-phosphorylatable Chk1-derived peptide. In such embodiments, phosphorylation of the phosphorylatable detection substrate in a test spot indicates that the test compound has no effect or a positive effect on SSB DDR activity. Increased phosphorylation of the phosphorylatable detection substrate, as compared to the positive control spot indicates that the test compound increases/upregulates a SSB DDR activity. Absence of phosphorylation or reduced phosphorylation of the phosphorylatable Chk1-derived peptide (compared to the positive control spot) in the test spot indicates that the test compound suppresses/inhibits an SSB DDR activity. In embodiments, the positive indicator of SSB DDR activity is a phosphorylatable Chk1-derived peptide having SEQ ID NO: 4. In embodiments, the negative indicator of SSB DDR activity is a non-phosphorylatable Chk1-derived peptide having SEQ ID NO: 5. Skilled artisans will recognize that other compounds (such as, but not limited to, other phosphorylatable and non-phosphorylatable peptides) can be used as positive and negative indicators of SSB DDR activity and are intended to be within the scope of the present disclosure.
An embodiment of a high-throughput system for identification of small-molecule modulators of DDR for SSB repair is illustrated in
If test compounds are identified as modulators using the methods and systems of the present disclosure, the modulatory effect of the compounds can be validated via additional testing, such as, but not limited to using immunoblotting and/or gel electrophoresis or other methodologies to detect, e.g., APE2's 3′-5′ exonuclease activity in vitro; the binding of APE2 Zf-GRF to ssDNA; DNA end resection of FAM-dsDNA-SSB in the HSS system; and the defined SSB-induced ATR-Chk1 DDR pathway activation in the HSS system. Such methods are described in greater detail in the examples below.
A Small Molecule Inhibitor of SSB Signaling and Methods of Using the Inhibitor
The above-described methods and systems of the present disclosure helped identify APE2 inhibitory activity of a known small molecule. Celastrol (chemical name: 3-Hydroxy-9β,13α-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid) is a quinone methide triterpene from Tripterygium wilfordii (also known as Thunder of God Vine). Although has been used as a natural medicine in China for many years (Yang et al., 2006), and evidence suggests that Celastrol exhibits anti-tumor activities in a variety of different types of cancers, it was not known to have any role in SSB signaling and/or the SSB DDR repair pathway. The studies presented in Example 3 below demonstrate that Celastrol surprisingly inhibited the binding of APE2 Zf-GRF to ssDNA in vitro, and the addition of Celastrol to the SSB signaling and repair system described above impaired the defined SSB-induced Chk1 phosphorylation. These data demonstrate that Celastrol has a distinct role in preventing the binding of APE2 Zf-GRF to ssDNA and APE2's critical function in SSB signaling in the HSS system. Additional details are provided in Example 3, below. Based on these results, Celastrol was identified as an inhibitor of SSB DDR activity. Thus, embodiments of the present disclosure also include a method of inhibiting single-strand break (SSB) signaling by contacting a composition of DNA molecules, wherein at least a portion of the DNA molecules have single-strand breaks, with an effective amount of a small molecule inhibitor 3-Hydroxy-9β,13α-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid (Celastrol), where the amount of Celastrol is sufficient to inhibit SSB repair in the DNA molecule.
In embodiments, methods of the present disclosure also include actively inhibiting SSB repair in at least one cell by contacting the at least one cell with an effective amount of 3-Hydroxy-9β,13α-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid. In embodiments the cell is a mammalian cell, such as, but not limited to a human cell. In embodiments, the cell is isolated from a mammal before the contacting step. In embodiments, contacting the cell with the Celastrol includes administration to the mammal. In embodiments the mammal has been diagnosed with a need for inhibiting SSB repair activity prior to the administration to the mammal. In some embodiments the mammal has been diagnosed with a need for treatment of a disorder (such as, but not limited to cancer) related to an SSB repair activity dysfunction prior to the administering step. In embodiments, the method also includes a step of identifying a mammal with a need for inhibiting SSB repair activity.
Additional details regarding the methods and compositions of the present disclosure are provided in the Examples below. The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present disclosure to its fullest extent. It should be emphasized that the embodiments of the present disclosure, particularly, any “preferred” embodiments, are merely possible examples of the implementations, merely set forth for a clear understanding of the principles of the disclosure. Many variations and modifications may be made to the above-described embodiment(s) of the disclosure without departing substantially from the spirit and principles of the disclosure. All such modifications and variations are intended to be included herein within the scope of this disclosure, and protected by the following claims.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the compositions and compounds disclosed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
It should be noted that ratios, concentrations, amounts, and other numerical data may be expressed herein in a range format. It is to be understood that such a range format is used for convenience and brevity, and thus, should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. To illustrate, a concentration range of “about 0.1% to about 5%” should be interpreted to include not only the explicitly recited concentration of about 0.1 wt % to about 5 wt %, but also include individual concentrations (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%) within the indicated range. In an embodiment, the term “about” can include traditional rounding according to significant figures of the numerical value, as defined above. In addition, the phrase “about ‘x’ to ‘y’” includes “about ‘x’ to about ‘y’”.
The present example describes systems and methods used to further study and elucidate the mechanisms of SSB signaling and repair. As the most common type of DNA damage, DNA SSBs are primarily repaired by the SSB repair mechanism. If not repaired properly or promptly, unrepaired SSBs lead to genome stability and have been implicated in cancer and neurodegenerative diseases. However, it remains unknown how unrepaired SSBs are recognized by DNA damage response (DDR) pathway, largely because of the lack a feasible experimental system. Here, we demonstrate that an ATR-dependent checkpoint signaling is activated by a defined plasmid-based site-specific SSB structure in Xenopus HSS (high-speed supernatant) system (
Experimental Procedures Related to Chromatin and Extracts of Xenopus laevis
The care and use of Xenopus laevis was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of North Carolina at Charlotte. The preparation of Xenopus LSS, HSS, and NPE were described previously (35,36,39, which are hereby incorporated by reference herein). Immunodepletion of target protein in HSS was performed with a similar procedure as immunodepletion in LSS as previously described (24,32, which are hereby incorporated by reference herein). DNA synthesis analysis was performed as previously described (11,35, which are hereby incorporated by reference herein). ImageQuat software was used to quantify the DNA synthesis from HSS/NPE system. Chromatin fractions were isolated using similar procedures described previously (24,40, hereby incorporated by reference herein). DNA-bound fractions from the HSS system were isolated after spinning extracts through a sucrose cushion (0.9 M sucrose, 2.5 mM MgCl2, 50 mM KCl, 10 mM HEPES, pH7.7) at 10,000 rpm for 2 minutes at 4° C. with a swinging bucket.
Plasmid pUC19 (SEQ ID NO: 1, + strand) was used as a template for designing a site-specific single-strand break (SSB) structure. There are four recognition sites on pUC19 for Nt.BstNBI, designated as site1 (nt 427-431 on (+) strand), site2 (nt 1177-1181 on (+) strand), site3 (nt 706-710 on (−) strand), and site4 (nt 1694-1698 on (−) strand). The plasmid pS (SEQ ID NO: 2) was generated by mutanting pUC19 on three sites (e.g., site2, site3, and site4) sequentially with three pairs of primers (SEQ ID NOs: 9-14, forward and reverse primers for mutant sites 4, 3, and 2, as indicated in Table 2, below) using QuikChange 11 XL site-directed mutagenesis kit. The mutations were verified and confirmed by DNA sequencing. Qiagen plasmid midi kit was utilized to obtain large amounts of the pS plasmid.
To generate a defined SSB between C435 and T436, the pS was treated with Nt. BstNBI (10 U/μg) for 2 hours at 55° C. and CIP (calf intestine phosphatase, 10 U/μg) for 1 hour at 30° C. to remove the 5′-P of T436. The SSB plasmid was purified from agarose via QIAquick gel extraction kit and optionally purified by Phenol-Chloroform extraction. To generate DSB plasmid, the pS was treated with SbfI-HF at 37° C. and CIP at 37° C. sequentially. The DSB plasmid was purified from agarose via QIAquick gel extraction kit and then optionally purified by Phenol-Chloroform extraction.
For better visualization on gel analysis, a FAM-SSB structure was generated by PCR using the pS as template following by nicking enzyme treatment. The primers having SEQ ID NOs: 15 and 16 were used for PCR amplification. The 70 bp dsDNA PCR product (i.e., bp 406-475 of the pS plasmid (SEQ ID NO: 2)) was purified from agarose via QIAquick gel extraction kit and further treated with Nt. BstNBI (10 U/μg) for 2 hours at 55° C. and CIP (10 U/μg) for 1 hour at 30° C. The FAM-SSB structure was purified from agarose via QIAquick gel extraction kit and then purified by Phenol-Chloroform extraction.
Recombinant pGEX-4T1-WT APE2-ZF was generated by cloning the ZF domain (nt 1478-1666) of xIAPE2 (GenBank: BC077433, Xenopus Gene Collection IMAGE ID: 4030411), which corresponds to the aa 456-517, into EcoRI- and XhoI-digested pGEX-4T1. Recombinant pET28a-PCNA was generated by subcloning full-length coding region (nt 39-824) of xIPCNA (GenBank: BC057758, Xenopus Gene Collection IMAGE ID:5049027) into BamHl- and Notl-digested pET28a using primer pair F-PCNA and R-PCNA (SEQ ID NOs: 17 and 18, respectively). Recombinant pGEX-4T1-XRCC1 was generated by cloning the coding region (nt 164-2119) of xIXRCC1 (GenBank: BC045032, Xenopus Gene Collection IMAGE ID:5543195) into EcoRI- and XhoI-digested pGEX-4T1 using primers F-XRCC1 and R-XRCC1 (SEQ ID NOs: 19 and 20, respectively). Recombinant pGEX-4T1-APE1 was generated by cloning the coding region (nt 119-1069) of xIAPE1 (GenBank: BC072056, Xenopus Gene Collection IMAGE ID: 4202632) into BamHl- and XhoI-digested pGEX-4T1.
Point mutants of recombinant DNA were generated with QuikChange IIXL Site-Directed Mutagenesis kit (Agilent). Recombinant plasmids were made via QIAprep spin miniprep kit following vendor's standard protocol. Myc-tagged recombinant proteins were generated with various pCS2+MT-derived recombinant plasmids and TNT SP6 Quick Coupled Transcription/Translation System (Promega) according to the manufacturer's protocol. GST- or His-tagged recombinant proteins were expressed and purified in E. coli DE3/BL21 following vendor's standard protocol. Purified recombinant proteins were confirmed on coomassie-stained SDS-PAGE gels with a range of BSA standards and a pre-stained protein ladder.
Anti-XRCC1 antibodies were raised in rabbits against GST-XRCC1 (Cocalico Biologicals). Anti-Xenopus APE2 antibodies was described previously (24). Antibodies against ATR and Claspin were provided by Dr. Karlene Cimprich (33,41). Antibodies against ATRIP, Rad9, and Rad17 were provided by Dr. Howard Lindsay (42). Antibodies against TopBP1 and RPA32 were provided by Dr. Matthew Michael (11). Antibodies against PARP1 was provided from Dr. Yoshiaki Azuma (43). Antibodies against human APE2 was provide by Drs. Yusaku Nakabeppu and Daisuke Tsuchimoto (44). Antibodies against RPA32 phosphorylation at Ser33 and Rad17 phosphorylation at Ser645 were purchased from Bethyl Laboratories. Antibodies against Chk1 phosphorylation at Ser345 were purchased from Cell Signaling Technology. Antibodies against Histone 3 were purchased from Abcam. Antibodies against Chk1, GST, His, Myc, PCNA, and Tubulin were purchased from Santa Cruz Biotechnology. Antibodies against human Chk1 and human RPA32 were purchased from Cell Signaling Technology and Thermo Scientific, respectively.
For the GST-pull-down experiments from HSS, 5 μg of GST or GST-tagged recombinant proteins were added to 200 μL Xenopus HSS. After an hour of incubation, an aliquot of egg extract mixture was collected as Input and the remaining extract mixture was diluted with 200 μL Interaction Buffer (100 mM NaCl, 5 mM MgCl2, 10% (vol/vol) glycerol, 0.1% Nonidet P-40, 20 mM Tris-HCl at pH 8.0). Then, 30 μL of glutathione beads that were resuspended in 200 μL interaction buffer were added to the diluted egg extracts. After 1 h incubation at room temperature, beads were washed with Interaction Buffer two times. Then, the bead-bound fractions and Input were analyzed via immunoblotting.
For the GST-pull-down experiment from a buffer, 5 μg of GST or GST-tagged recombinant proteins, and 5 μg of WT or mutant His-tagged PCNA were added to 200 μL Interaction Buffer. After an hour of incubation, an aliquot of the mixture was collected as Input and the remaining mixture was supplemented with 100 μL interaction buffer that contains 30 μL glutathione beads. After 1 h incubation at room temperature, beads were washed with Interaction Buffer two times. Then, the bead-bound fractions and the Input were analyzed via immunoblotting.
Analysis of DNA Repair Products from the HSS System
Nuclease-free water was added to each reaction of HSS that was incubated with SSB or DSB plasmid to a total of 300 μL. Equal volume of phenol-chloroform was added to the mixture and resuspended up and down 5 times and spin for 5 minutes at 13,000 rpm at room temperature. The top aqueous layer was transferred to a new tube and repeat phenol-chloroform extraction. Then sodium acetate (pH5.0, a final concentration of 0.3 M) and glycogen (a final concentration of 1 μg/μl) as well as ethanol (100%, 2.5-fold volume) were added to the aqueous solution, which was incubated for 30 minutes at −70° C. The mixture was centrifuged for 15 minutes at 13,000 rpm at room temperature. The pellet was washed by cold 70% ethanol and air-dry for 30 minutes before resuspension with nuclease-free water. Then the purified DNA repair products were analyzed on agarose gel and stained with ethidium bromide.
The FAM-SSB structure was added to mock- or APE2-depleted HSS, which was supplemented with VVT/mutant Myc-tagged APE2, respectively. After different time of incubation at room temperature, reactions were quenched with equal volume of TBE-Urea Sample Buffer (Invitrogen), denatured at 95° C. for 5 minutes, and cooled at 4° C. for 2 minutes. Samples were examined on 20% TBE-Urea gel and imaged on Typhoon 8600 and viewed using ImageQuant software.
Previous biochemistry analysis has indicated that APE1 can resect nicked dsDNA into 1-3 nt gap in the 3′-5′ direction in vitro (45). To generate a FAM-labeled gapped structure, it was found that the recombinant GST-APE1 resected FAM-labeled SSB substrate in the 3′-5′ direction in a dose-dependent manner (see
For the ssDNA binding assays in a buffer using GST or GST-tagged proteins, 40 μL of biotin-ssDNA (SEQ ID NO: 21, 80 nt, 100 μM) was added to 40 μL of Streptavidin Dynabeads in 2× B&W Buffer (2M NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH7.5), and incubated for 15 minutes at room temperature. After separating beads from buffer, the beads were washed by 2× B&W Buffer for three times and resuspended in 100 μL of Buffer B (80 mM NaCl, 20 mM 8-Glycerophosphate, 2.5 mM EGTA, 0.01% NP-40, 10 mM MgCl2, 100 ug/mL BSA, 10 mM DTT, and 10 mM HEPES-KOH, pH7.5). Then 20 μg of GST or GST-tagged proteins in 100 μL of Buffer B was added to the 80 nt-ssDNA-coupled beads in 100 μL of Buffer B. After a 30-minute incubation at 4° C., an aliquot of mixture was collected as input, and the beads were washed for three times with Buffer A (80 mM NaCl, 20 mM β-Glycerophosphate, 2.5 mM EGTA, 0.01% NP-40, and 10 mM HEPES-KOH, pH7.5). The Input and Bead-bound fractions were examined via immunoblotting analysis.
For the ssDNA binding assays in the HSS system, different lengths of Biotin-ssDNA (i.e., 0, 10 (SEQ ID NO: 25), 20 (SEQ ID NO: 24), 40 (SEQ ID NO: 23), 60 (SEQ ID NO: 22), and 80 (SEQ ID NO: 21)) were coupled to Streptavidin Dynabeads using a similar approach as above described, and resuspended in 200 μL of Buffer B. Then, the 200 μL of beads coupled with ssDNA was added to equal volume of diluted HSS (1:1 v/v dilution with Buffer B). After 1-hour incubation, an aliquot of the mixture was collected as Input, and the beads were washed with Buffer A three times. The Input and Bead-bound fractions were examined via immunoblotting analysis.
For the gapped DNA binding assays with purified proteins, biotin-gapped DNA structure was prepared in a similar approach to that for the FAM-gapped DNA structure with the exception that biotin was covalently linked to the 5′ side of one primer. The coupling of biotin-gapped DNA structure to Streptavidin Dynabeads, protein incubation and bead washing process were performed following the protocol for ssDNA binding analysis in a buffer as described above.
Human U2OS cells were purchased from the American Type Culture Collection (ATCC) and cultured in Dulbecco's Modified Eagle Medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS, Invitrogen), penicillin (100 U/mL) and streptomycin (100 μg/mL, Life Technologies) in incubator at 37° C. and 5% CO2. For G1 synchronization, cells were first blocked in S phase with 2 mM thymidine for 24 hours and released for 4 hours, then blocked in M phase with 100 ng/mL nocodazole for 12 hours and released for 6 hours, and finally blocked in G1 phase with DMEM without FBS for 96 hours. Cells were treated with VE-822 (5 μM) in culture medium for 1 hour followed by hydrogen peroxide treatment (1.25 mM) for 4 hours. Then cells were collected and split for immunoblotting analysis and FACS analysis. For immunoblotting analysis, equal total proteins of cell lysates (10 μg per lane) were loaded and Tubulin was used for loading control. For FACS analysis, cells were further fixed and stained with DAPI followed by cell cycle profiling using FACS machine (BD LSRFortessa) following manufacturer's standard protocol.
ImageQuant software was utilized to quantify the incorporation of [32P-α]-dATP to newly synthesized DNA from the HSS/NPE system. ImageQuant was used to visualize gels from SSB end resection assays. ImageJ was utilized to view gels from exonuclease assays.
A Defined SSB Structure can be Repaired in the HSS System
In the present example, a pUC19-derived plasmid, pS, was generated that contains only one recognition sequence for a nicking endonuclease Nt.BstNBI (
To examine SSB repair process in the HSS system, it was found that the nicked version was converted into a circular version after incubation in HSS for different lengths of time, indicating that the SSB structure is gradually repaired in HSS (Lane 6-11,
A Distinct ATR-Chk1 DNA Damage Response Pathway is Induced by a Defined SSB Structure in the HSS System
To determine whether a defined SSB structure triggers a DDR pathway, different concentrations of SSB or CTL plasmid structure were added to HSS, followed by immunoblotting analysis after a 30-minute incubation. This revealed that 75 ng/μL (43 nM) of the defined SSB plasmid, but not CTL plasmid, triggered a robust Chk1 phosphorylation at S344 in the HSS (equivalent to Chk1 phosphorylation at S345 in humans), suggesting that the SSB structure induces a unique checkpoint signaling in the HSS in a dose-dependent manner (
Although DNA replication is required for ATR-Chk1 checkpoint activation in response to stalled replication forks and oxidative stress (32,33,46), the defined SSB-induced Chk1 phosphorylation was not impaired by the addition of MCM helicase inhibitor recombinant geminin protein, suggesting that DNA replication is dispensable for the SSB-induced Chk1 phosphorylation in the HSS system (
To further determine whether the defined SSB-induced Chk1 phosphorylation is ATR-dependent, endogenous ATRIP was removed via immunodepletion using anti-ATRIP antibodies which also co-depleted endogenous ATR, as ATR and ATRIP form a tight complex in Xenopus egg extracts (
To identify the significance of SSB-induced ATR activation, whether SSB repair is affected by ATR in the HSS system was examined. It was found that the addition of ATR specific inhibitor VE-822 compromised the SSB repair in the HSS system (
Previous studies have shown that TopBP1, Rad9, and Claspin are canonical checkpoint proteins required for the ATR-Chk1 DDR pathway (8,34,40). Notably, the defined SSB-induced Chk1 phosphorylation was compromised when TopBP1, Rad9 or Claspin was immunodepleted in the HSS, respectively, suggesting the requirement of these checkpoint proteins for SSB signaling (
APE2 Zf-GRF Associates with PCNA C-Terminal Motif as a Distinct Mode of APE2-PCNA Interaction
APE2 interacts with PCNA's IDCL motif via its PIP box in yeast, Xenopus, and humans (
To identify critical residues within APE2 Zf-GRF for its interaction with PCNA, three point mutants were generated in GST-APE2-ZF (i.e., G483A-R484A, F486A-Y487A, and C470A). GST-pulldown assays demonstrated that G483A-R484A, F486A-Y487A, and C470A GST-APE2-ZF failed to efficiently interact with recombinant PCNA in an interaction buffer, in comparison to WT GST-APE2-ZF (
To characterize the biological significance of APE2 Zf-GRF interaction with PCNA CTM motif, VVT or C470A Myc-tagged APE2 was added back to APE2-depleted HSS, and WT, but not C470A, APE2 was found to rescue the SSB-induced Chk1 phosphorylation in APE2-depleted HSS (
Next, the DNA-bound fractions were isolated from HSS and the abundance of checkpoint proteins via immunoblotting analysis were examined. Although PCNA was recruited to both CTL and SSB plasmid, a checkpoint protein complex, including ATR, ATRIP, TopBP1, and Rad9, was assembled onto SSB plasmid, but not CTL plasmid, in the HSS system (DNA-bound fractions, Lane 1-2,
To further investigate the SSB end resection by APE2 per se, a FAM-labeled dsDNA was generated in which a SSB is localized at a defined location in the upper strand, designated as FAM-SSB (70 bp in total,
Using reconstitution system with purified proteins in vitro, DNA end resection of a gapped dsDNA structure was examined, in which the FAM-SSB was pretreated with recombinant APE1 to generate approximately 1-3 nt gap (
The different requirement of APE2 Zf-GRF interaction with PCNA CTM for SSB end resection in the HSS and in purified protein system in vitro may be because of a previously unidentified negative regulatory factor in the HSS system. It is believed that the Zf-GRF-PCNA CTM interaction may be needed to overcome such inhibition of SSB end resection in the HSS system. Together, the above data suggest that the APE2 Zf-GRF-PCNA interaction promotes the ATR-Chk1 DDR pathway activation from a site-specific SSB structure in a cell-free eukaryotic system such as illustrated in the schematic shown in
It is believed that this is the first report that a defined SSB triggers the ATR-Chk1 DDR pathway in a eukaryotic experimental system. Based on evidence in this study, a working model for the SSB-induced ATR-Chk1 DDR pathway is proposed as illustrated in
The SSB signaling system of the present disclosure requires only HSS but not the addition of NPE, which is different from previously established reconstitution systems, such as ATR DDR pathway activation by 3′-primed ssDNA or defined ICLs using Xenopus HSS and NPE combined systems (53,54). The defined SSB structure is resected by APE2 in the 3′ to 5′ direction to generate a longer stretch of ssDNA, which is in line with the previously established general model for ATR-Chk1 DDR pathway activation (7,8,14,53). To test whether the SSB plasmid triggers ATR activation in NPE, it was found that no detectable Chk1 phosphorylation was induced by SSB plasmid in NPE (
One striking feature of this experimental system is that SSB signaling is replication-independent in the HSS (
The two modes of APE2-PCNA interaction are intriguing. APE2 interacts with PCNA's IDCL motif via its PIP box and associates with ssDNA via its Zf-GRF motif (24,30-32). Importantly, the present results demonstrated that APE2 Zf-GRF also interacts with PCNA, mainly through PCNA's CTM region. Therefore, two modes of APE2-PCNA interaction are proposed: APE2 PIP box-PCNA IDCL interaction and APE2 Zf-GRF-PCNA CTM interaction are designed as Mode I and Mode II interaction, respectively (
Furthermore, from these data, it appears that the two modes of APE2-PCNA interaction are neither required for nor mutually exclusive to each other. The present observations indicate that the Mode I interaction plays a major role in APE2 recruitment to SSB sites whereas the Mode II interaction plays an important role in APE2 activation in the HSS system. Nonetheless, the biological significance of Mode II of APE2-PCNA interaction is evidenced by deficiency of SSB end resection and SSB signaling by the mutant C470A APE2 in the HSS system (
In addition, both IDCL and CTM regions within PCNA are important for PCNA-stimulated 3′-5′ exonuclease activity of APE2 in vitro (
Previous studies have demonstrated that the homologue residues of E34A and D273A from yeast and human cells are exonuclease defective APE2 mutants (27,57). Previous studies have demonstrated that the E34A APE2 and D273A APE2 failed to rescue the hydrogen peroxide-induced Chk1 phosphorylation in APE2-depleted LSS system (24). To verify the Xenopus E34A APE2 and D273A APE2 are indeed exonuclease deficient mutants, their exonuclease activity was tested using FAM-labeled gapped DNA structure as template in vitro. Consistent with previous studies on APE2 in other species, the PCNA-promoted exonuclease activity of Xenopus APE2 was significantly decreased in E34A APE2 and D273A APE2 (FIG. 15B). Notably, WT, but not E34A or D273A, Myc-APE2 rescued Chk1 phosphorylation in APE2-depleted HSS (“extract” panel,
APE2 Zf-GRF interaction with PCNA is a distinct feature compared with ssDNA interaction. There are three types of mutants in APE2 Zf-GRF in terms of PCNA and ssDNA interaction: (I) C470A Zf-GRF and F486A-Y487A Zf-GRF are deficient for PCNA interaction but proficient for ssDNA interaction, (II) R502A APE2 Zf-GRF is deficient for ssDNA interaction but proficient for PCNA interaction (32), and (III) G483A-R484A APE2 Zf-GRF is defective for both PCNA association and ssDNA interaction (
SSB end resection has unique characteristics in comparison to other DNA end processing pathways such as DSB end resection. In this study, substantial data is presented to show that a site-specific SSB structure triggers an ATR-Chk1 DDR pathway via SSB end resection in a eukaryotic cell-free system. One distinct feature of SSB end resection is the critical role of APE2's 3′-5′ exonuclease activity (
In addition, previous studies demonstrate that ATR and ATRIP preferentially bind to approximately 70 nt to 80 nt ssDNA coated with RPA in in vitro binding assays (10). Consistent with this, a gapped plasmid with 68 nt ssDNA is sufficient to trigger an ATR-Chk1 DDR pathway in a DNA-PKcs-dependent manner in human cell-free extracts (62). To test whether ATR and ATRIP are recruited to this short stretch of ssDNA (18 nt-26 nt), it was discovered that as short as 20 nt ssDNA was sufficient for binding of RPA, ATR and ATRIP in the HSS system (
From COSMIC analysis (cancer.sanger.ac.uk/cancergenome/projects/cosmic) of 45 cancer patients with somatic mutations in APE2, 33 missense point mutations were found in APE2, out of which 21 mutant residues of human APE2 are identical to Xenopus APE2 in homologue analysis. These 21 substitution missense point mutants in human APE2 are converted into Xenopus APE2: G10E, T38S, V491, G51S, R62H, A69S, A79S, E83G, L110R, E152K, R159C, R208C, R244C, R264H, H300Q, A314T, E343K, A366V, G456E, E468G, and R484H. It was found that 15 residues are in the N-terminal EEP domain, and two mutant residues (E468 and R484) are in the Zf-GRF domain. In particular, the R484H mutant within APE2 Zf-GRF may be deficient for PCNA interaction and ssDNA interaction. In addition, one nonsense substitution in human APE2 (c.1342G>T, p.E448*) was confirmed as a somatic mutation in a lung carcinoma patient (TCGA-75-6211-01), leading to a mutant APE2 protein that lacks the whole Zf-GRF domain. These somatic mutations in cancer patients suggest that the Zf-GRF domain of APE2 may have biological significance via its checkpoint function. Dysfunctions in DNA repair and DDR signaling pathways are implicated in cancer development (6). Importantly, a variety of DNA repair and DDR proteins including ATR and Chk1 become therapeutic targets and are currently being tested in the laboratory and clinical studies (63). A better understanding of DDR pathway activation in response to SSBs has implications in new avenues of cancer treatment. Findings from these experiments will impact future translational studies such as anti-cancer therapies via the modulation of novel role of APE2 in SSB signaling using mammalian cell lines or mice models. Overall, the present evidence using defined SSB end resection and SSB signaling in Xenopus provides novel insights into SSB-induced DDR pathway by APE2 in a eukaryotic cell-free system.
Table 1 below provides information including key reagents and resources used in Example 1. Antibodies, chemicals, and recombinant DNA and proteins, critical commercial assays, and software are summarized in this table. Oligonucleotides used in this example are presented with the sequence information, below.
As demonstrated in Example 1 above, APE2 is composed of three conserved domains: A N-terminal endonuclease/exonuclease/phosphatase (EEP) domain, a middle PIP box domain, and a C-terminal Zf-GRF domain (
Celastrol is a quinone methide triterpene from Tripterygium wilfordii (also known as Thunder of God Vine) that has been used as a natural medicine in China for many years (Yang et al., 2006). Accumulating evidence suggests that Celastrol exhibits anti-tumor activities in a variety of different types of cancers, including prostate cancer (Dai et al., 2009; Yang et al., 2006), breast cancer (Raja et al., 2014; Shrivastava et al., 2015), pancreatic cancer (Yadav et al., 2010), lung cancer (Liu et al., 2014; Wang et al., 2015), and glioblastoma (Boridy et al., 2014). Numerous molecule targets of Celastrol have been identified, such as IKK-alpha, IKK-beta, cdc37, p23, heat short factor-1, and proteamsomes (Chadli et al., 2010; Lee et al., 2006; Sreeramulu et al., 2009; Wang et al., 2015). However, it remains unknown whether Celastrol plays a role in the SSB signaling and repair pathways.
Example 1 demonstrated that GST-APE2 ZF can bind to ssDNA in vitro (
The above-described SSB signaling technology has established a tractable experimental system to investigate all aspects of the SSB signaling. One particular significant application of the SSB technology is to identify small molecule inhibitors of APE2 functions in the SSB signaling via a forward chemical genetic screen, followed by validation via established functional analyses described above. The present example describes systems using the SSB/HSS systems of the present disclosure for screening compound libraries for modulators (e.g., enhancers or inhibitors) of SSB DDR activity.
Screening Small Molecule Libraries and Identify New Inhibitor of APE2 in Ssb Signaling.
A forward chemical genetic screen approach is used to identify small molecule inhibitors of APE2 functions in SSB signaling from available small molecule libraries as illustrated in
Briefly, SSB plasmid is added to Xenopus HSS and transferred to 96-well plates containing 88 compounds (columns 1-11) per plate. A12, B12, and C12 are used for positive controls with phosphorylatable Chk1 peptide. D12, E12, and F12 are used for negative controls with non-phosphorylatable control peptide. ATR inhibitor VE-822 is used as a control in positions G12 and H12. The activity of ATR was examined by measuring the incorporation of radiolabeled [gamma-32P]-ATP into a peptide derived from Chk1. The reactions are transferred to a 96-well p81 phosphocellulose plate, washed, dried, and exposed to a Phosphorlmager screen for visualization and quantification. The phosphorylation of Chk1 peptide is calculated for each sample according to the following formula: (value of sample−average of value of negative controls with control peptide)/(average value of 88 samples−average value of negative control). Percentages of inhibition of Chk1 peptide phosphorylation are calculated according to following formula: (1−(average of sample value−average value of negative controls)/(average value of positive controls−average value of negative controls))×100.
Validating the Identified Small Molecule Inhibitors of APE2 Functions in SSB Signaling.
Once hit small molecules are identified, the inhibitory effect of these molecules will be validated via several established approaches: (1) APE2's 3′-5′ exonuclease activity in vitro using the method; (2) The binding of APE2 Zf-GRF to ssDNA; (3) DNA end resection of FAM-dsDNA-SSB in the HSS system; (4) and the defined SSB-induced ATR-Chk1 DDR pathway activation in the HSS system, which are described in Example 1, above.
The following provides a brief description of oligonucleotide (DNA/RNA) and peptide sequences referred to in the present disclosure. This list may not be exhaustive and other sequences may be referred to by designations known to those of skill in the art.
This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/467,894, having the title “Single Strand Break Signaling in a Cell-Free System”, filed on Mar. 7, 2017, the disclosure of which is incorporated herein by reference in its entirety.
This invention was made with government support under GM114713 awarded by National Institutes of Health. The U.S. government has certain rights in this invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/065639 | 12/11/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62467894 | Mar 2017 | US |
